Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : LEO Pharma A/S
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Safety profile of innohep versus subcutaneous unfractionated Heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis
The primary objective of this study is to compare the safety of innohep and unfractionated heparin (UFH) in terms of Clinically Relevant Bleedings in elderly patients with impaired renal function for ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)
MAJ Il y a 4 ans
Fucidin® Cream in the Treatment of Impetigo A phase IV study comparing clinical and bacteriological efficacy of Fucidin® cream with Fucidin® cream vehicle in the treatment of impetigo in paediatric patients
To investigate the clinical and bacteriological efficacy of Fucidin® cream in the treatment of impetigo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Patient insights following use of LEO 90100 aerosol foam and Daivobet® gel in subjects with psoriasis vulgaris
To gather insight on how product attributes affect usability by investigating the factors that are thought to influence patient preference to topical anti-psoriatic treatments.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Safety and Efficacy of Calcipotriol plus Betamethasone Dipropionate Gel in Adolescent Subjects (Aged 12 to 16 Years, 11 months) with Scalp and Body Psoriasis Sicherheit und Wirkung von Calcipotriol plus Betamethasondipropionat-Gel bei jugendlichen Patienten (im Alter von 12 bis 16 Jahren und 11 Monaten) mit Psoriasis auf Kopfhaut und Körper
The primary objective is to evaluate the safety of once daily use of calcipotriol (50 mcg/g) plus betamethasone (0.5 mg/g) (as dipropionate) gel in adolescent subjects (aged 12 to 16 years, 11 months)...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Efficacy and safety of ingenol mebutate gel 0.015% compared to diclofenac sodium gel 3% in subjects with actinic keratoses on the face or scalp. Eficacia y seguridad de mebutato de ingenol en gel al 0,015 % en comparación con diclofenaco sódico en gel al 3 % en pacientes con queratosis actínicas en la cara o el cuero cabelludo
To compare the efficacy of daily application for 3 consecutive days of ingenol mebutate gel 0.015% with the efficacy of diclofenac sodium gel 3% for 90 days in subjects with AK on the face or scalp. ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
LEO 90100 aerosol foam compared to calcipotriol plus betamethasone dipropionate gel in subjects with psoriasis vulgaris
To compare the efficacy of treatment with LEO 90100 at Week 4 to that of calcipotriol plus betamethasone dipropionate (BDP) gel at Week 8 in subjects with psoriasis vulgaris
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Exploratory efficacy and safety, pharmacokinetics and dose-finding study of ATryn® (antithrombin alfa) in patients with disseminated intravascular coagulation associated with severe sepsis
The primary objective of the study is to explore the efficacy and safety of ATryn® for the treatment of disseminated intravascular coagulation (DIC) associated with severe sepsis, when administered by...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharmaceutical Products Ltd. A/S (LEO Pharma A/S)
MAJ Il y a 4 ans
Calcipotriol Plus Hydrocortisone in Psoriasis Vulgaris on the Face and on the Intertriginous Areas. A phase 3 study comparing an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g (LEO 80190 ointment) with calcipotriol 25 mcg/g in the ointment vehicle, hydrocortisone 10 mg/g in the ointment vehicle and the ointment vehicle alone, all applied once daily in the treatment of psoriasis vulgaris on the face and on the intertriginous areas, followed by a 52-week safety study in patients with psoriasis vulgaris on the face and on the intertriginous areas
To compare the efficacy of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g with calcipotriol 25 mcg/g in the ointment vehicle, hyd...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
Calcipotriol plus Betamethasone Dipropionate Gel Compared to DAIVONEX/DOVONEX Scalp Solution in Patients with Scalp Psoriasis. A phase III study comparing a gel containing calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate) used once daily with calcipotriol 50 mcg/ml in scalp solution used twice daily, in the treatment of scalp psoriasis
To compare the efficacy of 8 weeks, once daily treatment of calcipotriol plus betamethasone dipropionate gel with twice daily treatment of DAIVONEX/DOVONEX scalp solution, in the treatment of scalp ps...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
LEO Pharma A/S
MAJ Il y a 4 ans
not applicable
To compare the efficacy of twice daily application of LEO 124249 ointment 30 mg/g and LEO 124249 ointment vehicle for 6 weeks in the treatment of subjects with mild to moderate inverse psoriasis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Précédent
1
2
3
4
Suivant